Several non-invasive scoring systems have been developed to determine risk of advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). We examined the association between 4 scoring systems and incident severe liver disease and overall mortality in a large cohort of patients with biopsy-proven NAFLD.
N onalcoholic fatty liver disease (NAFLD) has become a major health problem worldwide because of its potential to evolve into cirrhosis, end-stage liver disease and hepatocellular carcinoma (HCC). [1] [2] [3] The natural history of NAFLD is highly variable, with most cases never developing cirrhosis or liver-related complications. Indeed, most patients with NAFLD eventually die from non-liver-related disease. 4, 5 The parameter with the best predictive capacity for both overall mortality and development of clinically significant liver disease, apart from age, is fibrosis stage. [5] [6] [7] [8] [9] Obviously, liver biopsy is unsuitable for screening of clinically significant fibrosis for a condition that affects approximately 25% of the adult population worldwide. 4 Therefore, methods to noninvasively identify advanced fibrosis in NAFLD is of high clinical interest. Such methods include transient elastography and other imaging-based approaches, but from a primary care perspective, such methods are cumbersome, expensive, and not suitable as a first-line approach to identify advanced fibrosis. There are several scoring systems based on clinical and biochemical data that have been validated in predicting presence of advanced fibrosis (stage 3-4) in NAFLD. The main benefit of these scores is their ability to exclude persons without advanced fibrosis (ie, their high negative predictive values). 10 However, there are few studies examining the ability of these scores to predict incident future mortality or clinically significant liver disease. Previous studies in biopsy-proven NAFLD has had relatively short follow-up periods (mean 5-12 years) [11] [12] [13] and low numbers of included patients (maximum ¼ 320). Larger cohorts with longer follow-up periods have defined NAFLD using blood-based algorithms, 14, 15 a method prone to misclassification bias.
Here, we used data from a previously published study 5 to examine the prognostic performance of several scoring systems on incident mortality and liver-related endpoints in a large cohort of patients with NAFLD diagnosed with liver biopsy and followed for a long duration.
Materials and Methods

Subjects
We conducted a retrospective cohort study including all patients diagnosed with biopsy-proven NAFLD, at the Karolinska University Hospital (Huddinge) and Linköping University Hospital, from 1971 to 2009. The methodology for generation of the cohort and the main results are available elsewhere. 5 Briefly, we identified all patients that underwent liver biopsy with the finding of steatosis at our institutions. All patients' medical charts were scrutinized in detail. Patients with causes for steatosis other than NAFLD or diagnosed with any concurrent liver disease during follow-up were excluded. Patients that reported daily alcohol consumption exceeding 30 g for men or 20 g for women at baseline or during follow-up were also excluded.
Histopathological Evaluation
One expert liver pathologist (R.H.) reviewed all available biopsies, which were scored according to the NAFLD activity score (NAS). 16 The fatty liver inhibition of progression algorithm was used to define presence of nonalcoholic steatohepatitis (NASH). 17 Fibrosis stage was scored according to the Kleiner classification on a 5-point scale (F0-F4). 16 Of note, 69 liver biopsies were not available for reassessment but had previously been reassessed by another experienced liver pathologist as part of a prior follow-up study 18 ; these were used for fibrosis staging but not for analysis of activity scores or presence of NASH, as the reproducibility for necroinflammatory changes between the 2 pathologists was low (kappa ¼ 0.062).
Baseline Characteristics
Diagnoses at the time of liver biopsy were registered from patient charts. Type 2 diabetes mellitus was defined as a registered diagnosis in patient charts, a nonfasting glucose value of !180 mg/dl or a fasting glucose value of !126 mg/dl, or having any antidiabetic medication prescribed. Hypertension was defined as a registered diagnosis in patient charts, a resting blood pressure of !140/90 mm Hg or having any antihypertensive medication prescribed. Weight and height were objectively measured by hospital staff and used to calculate body mass index (BMI).
Biochemical Variables
Routine biochemical variables within 1 month of liver biopsy were registered and included alanine aminotransferase (ALT) and aspartate aminotransferase (AST), albumin, bilirubin, alkaline phosphatase, and gammaglutamyl transferase levels, complete blood count, fasting cholesterol and triglycerides, fasting glucose, autoantibodies, and a1-antitrypsin levels. In cases with missing data, multiple imputation was used. 19 What You Need to Know Background We aimed to determine the accuracy of noninvasive scoring systems in determining risk of death or severity of liver disease in a large cohort of biopsyproven nonalcoholic fatty liver disease (NAFLD) patients.
Findings
Based on area under the receiver-operating characteristic curve values, the NAFLD fibrosis score and Fibrosis-4 index most accurately determined overall risk of death or severe liver disease compared with to aspartate aminotransferase-platelet ratio index and BARD (BMI, AST/ALT ratio, and diabetes mellitus). However, none of the scores had a high enough capacity to detect either outcomes to be directly used in a clinical setting.
Implications for patient care
New systems are needed to determine prognoses of patients with NAFLD.
Scoring Systems
Four noninvasive scoring systems that were originally created to distinguish between patients with and without advanced liver fibrosis (stage 0-2 vs stage 3-4) were calculated using the original reported formulas. [20] [21] [22] [23] The NFS, À1.675 þ 0.037 
Follow-Up
The personal identification number is a unique 10-digit code provided to all Swedish residents. We used the personal identification number to link the cohort to national, population-based registers. The National Patient Register holds data on hospitalizations since 1964, and on outpatient visits in specialized care since 2001. The validity of hospital discharge diagnoses obtained is between 85% and 95% depending on diagnosis. 24 The Causes of Death Register contains data regarding the causes of death of all Swedish inhabitants, including if the person died abroad. It is mandatory for the responsible physician to report the underlying cause of death (eg, HCC) and any disease that could have contributed to the death of the individual (eg, liver cirrhosis). 25 The Swedish Cancer Register contains data on verified solid and nonsolid tumors. The completeness of the register is around 96%. 26 
Outcomes
The registers were used to ascertain both overall mortality and all cases of a composite variable endpoint during follow-up, termed severe liver disease. Severe liver disease consisted of clinically relevant diagnoses that are unlikely to be missed in the registers. Severe liver disease was defined as the first recorded International Classification of Diseases (ICD) code for liver failure, cirrhosis, HCC, decompensated liver disease, or liver transplantation found in any of the registers during follow-up. This included liver-related mortality, which was separately investigated as a single outcome. Liverrelated mortality was defined as having an ICD code corresponding to severe liver disease mentioned as the primary cause of death in the Causes of Death Register.
Decompensated liver disease was defined as an ICD code for esophageal varices (bleeding or not bleeding), ascites, or hepatic encephalopathy, while liver failure was defined as having a specific ICD code for liver failure only. A table of all diagnoses used to define the outcomes is presented in Supplementary Table 1.
Statistical Analysis
Data are expressed as median (interquartile range) or as total number with percentage where applicable, unless otherwise specified. The diagnostic accuracy of the 4 scoring systems to distinguish between patients with and without increased risk for the outcomes was examined by calculating the area under the receiver-operating characteristic curve (AUROC) for each scoring system. We compared each score against the 3 others using receiver-operating characteristic area equality tests (STATA roccomp command) (STATA 13; StataCorp, College Station, TX). Cox regression was used to examine the association between each risk category, using the lowrisk category as reference. A crude model was constructed for each score, only using the score per se without adjustments (as would be the case in a clinical setting). Additionally, adjusted models were applied for each score to allow for adjustment for parameters not included in all scores (eg, age or type 2 diabetes). The NFS was thereby further adjusted for sex and hypertension. The FIB-4 was adjusted for sex, type 2 diabetes and hypertension. The APRI was adjusted for age, sex, type 2 diabetes, BMI, and hypertension. BARD was adjusted for age, sex, and hypertension. C-statistics were calculated for the unadjusted and adjusted models to further examine the predictive capacity for each score. 27 The end of follow-up was December 31, 2014, or time of event (whichever occurred earliest). All analyses were performed in STATA.
Sensitivity Analysis
As the NFS and FIB-4 scores might perform differently across different categories of age, we applied the cutoff levels from McPherson et al, 28 with lower cutoffs for NFS and FIB-4 and excluding cases below 35 years of age.
Ethical Considerations
The regional ethics committees at Karolinska Institutet and Linköping University approved the study (Dnr 2011/905-31/2 and 2015/1591-32).
Results
Baseline characteristics of the cohort are presented in Table 1 . Median age was 50 years and men comprised 62% of the cohort . The majority (66%) of the participants had NASH, and 12% had advanced (stage 3-4) fibrosis. During a mean follow-up of 19.9 AE 8.7 years (range, 0.4-40 years of age), 214 (33%) persons died and 76 persons (12%) developed severe liver disease. There were 17 (2.6%) cases of death directly attributed to liver disease and there were 12 (1.9%) cases of HCC. Absolute numbers and percentages of patients that died or developed severe liver disease, stratified on each risk score group, are presented in Table 2 . Table 2 also presents numbers and percentages of patients with fibrosis stage 3-4 as diagnosed on liver biopsy and on patients that died of liver disease per risk score group.
Based on receiver-operating characteristic analysis, the NFS and FIB-4 performed similarly in predicting both overall mortality and severe liver disease, while BARD and APRI had a lower predictive capacity. Both FIB-4 and NFS predicted overall mortality better than APRI or BARD (P < .01 for all comparisons), while there was no difference between NFS and FIB-4 (P ¼ .92). For severe liver disease, NFS, FIB-4, and APRI performed similarly (P > .05 for comparisons between all scores), while all 3 scores all outperformed the BARD score (P < .05 for all comparisons). AUROCs for overall mortality and severe liver disease for all 4 scores are presented in Figure 1A and B.
Cox regression estimates and C-statistics for all scores stratified on the risk for advanced fibrosis (low, intermediate, high) are presented in Table 3 . In unadjusted analysis, there was an increased risk for severe liver disease in the intermediate-and high-risk groups as compared with the low-risk group across all scoring systems. Based on C-statistics, the score with the highest predictive capacity for development of severe liver disease was the FIB-4 score (0.734), closely followed by the NFS (0.728). For overall mortality, similar results were found (Table 3 ). For comparison, the true fibrosis stage based on liver biopsy was superior in prediction of severe liver disease, but not for overall mortality (Table 3) .
The adjusted models performed significantly better than the unadjusted scoring systems based on C-statistics. Here, C-statistics were similar across all scoring systems, with the highest value for severe liver disease found for the APRI and FIB-4 (0.800). Regarding hazard ratios, the risk for severe liver disease was increased in the intermediate-and high-risk groups compared with the low-risk groups, with the highest hazard ratios for severe liver disease seen in the high-risk group for NFS. Again, fibrosis stage based on liver biopsy was superior in prediction of severe liver disease, but comparable to noninvasive scores for overall mortality ( 
Discussion
In this retrospective cohort study, we studied the predictive capacity of 4 commonly used noninvasive scoring systems used to identify advanced fibrosis in NAFLD for mortality and severe liver disease. We found that the scores with the highest predictive capacity, both for overall mortality and for severe liver disease, were the FIB-4 and the NFS. However, based on several analyses, all scores only predicted the endpoints to a fair degree. In multivariable modeling and after adding additional covariates to each score, prediction of both overall mortality and severe liver disease was greatly enhanced, as reflected by higher C-statistics. Thus, it seems reasonable to conclude that currently available scoring systems can to a certain extent predict outcomes in NAFLD, but that by adding additional data prediction can be improved. This can have several implications. First, prognoses in NAFLD should not be made solely on currently available noninvasive scores. Indeed, between 7% and 9% of patients within the low-risk groups in this study eventually developed severe liver disease, likely due to misclassification in the scores. Ideally, patients in low-risk groups should be retested within a few years' time to reduce misclassification bias, and patients in intermediate-or high-risk groups based on noninvasive scores should be tested for presence of advanced fibrosis with for instance transient elastography. This approach has previously been suggested, 29 but must be validated in future studies.
An additional finding is that also the predictive capacity of fibrosis stage per se was also improved by adding additional covariates. We interpret this as logical, as older patients with more comorbidities are more likely to experience events compared with younger and healthier patients with the same stage of fibrosis.
Second, more research attention should be given to develop new scores directly aimed at predicting prognoses in NAFLD. Here, one must also consider the different populations in which such scores should be used. The prevalence of a certain disease in a given population highly impacts the results of prediction models. The scores examined in this study have been developed from selected populations undergoing liver biopsy. Presence of advanced fibrosis in the original cohorts as well as in our study is much higher than in the general population, which is why results from this and other studies looking at selected populations from tertiary care cannot directly be extrapolated to a primary care setting. Thus, specific scores must be developed for a primary care setting.
Comparison With Previous Studies
Our results differ somewhat to previous studies. [11] [12] [13] [14] [15] [30] [31] [32] For example, compared with the paper by Angulo et al, 11 we found lower hazard ratios for both mortality and liver-related events and lower AUROCs for predicting the studied outcomes. This could be because differences in cohort characteristics. Only 12% of patients in our study had advanced fibrosis compared with 51% in the Angulo et al study. We also present a larger cohort (646 vs 320), and a longer follow-up duration (19.9 years vs 8.7 years). This suggests that our estimates could be more accurate, and more generalizable to populations with lower prevalence of advanced fibrosis. Our estimates for overall mortality are higher compared with results from Unalp-Arida and Ruhl, 15 who studied the impact of several scoring systems in NHANES data. The NHANES datasets are generated from a representative sample of the U.S. population, but defining NAFLD using blood-based NOTE. Values are n/n (%) or n (%). APRI, aspartate aminotransferase-platelet ratio index; BARD, BMI, AST/ALT ratio, and diabetes mellitus; FIB-4, Fibrosis-4; NAFLD, nonalcoholic fatty liver disease.
algorithms is prone to misclassification bias. Estimates for the outcome severe liver disease in our study is similar to the outcome liver-related mortality, used in the NHANES dataset. For instance, the unadjusted hazard ratio for high compared with low NFS was 10.2 in our study, and 9.8 in the Unalp-Arida and Ruhl 15 study. Presumably, the difference in estimates from the respective studies can be due to difference in the prevalence of baseline fibrosis stage in the respective cohorts, follow-up duration, and somewhat different statistical models being applied.
Strengths and Limitations
The main strengths of our study include the hitherto largest sample size in a biopsy-proven historical NAFLD cohort. Additionally, we present a long follow-up duration, which is vital to allow for enough events to occur. We have no loss to follow-up thanks to high-quality national registers. Misclassification of the exposure could be checked by having access to liver biopsy data, and we corrected missing data on clinical and biochemical parameters by multiple imputation. Misclassification of the outcome (overall mortality and severe liver disease) should also be minimal due to ascertainment of outcomes in national registers, and selection of "hard" endpoints that are likely to be captured by these registers. We were able to examine several scoring systems. This is also the first study to address this research question in a European population.
Limitations include a risk for selection bias. Indeed, this is true for all studies in biopsy-proven NAFLD. However, we had a low prevalence of baseline advanced fibrosis, perhaps due to the fact that liver biopsy was the main diagnostic tool for evaluation of elevated transaminases historically (the main cause for liver biopsy in this cohort). 5 Also, mortality in this cohort was similar compared with matched control subjects, as previously reported, 5 suggesting low risk for selection bias. We were unable to study the impact of modern tools in fibrosis estimation, such as patented blood-based tests, transient elastography and magnetic resonance-based techniques.
Hepatic fibrosis is the parameter that best predicts risk of future complications in NAFLD. [5] [6] [7] All noninvasive serum algorithms evaluated in the present study are based on the evaluation of common clinical parameters or functional alterations in the liver, alterations that do not necessarily reflect extracellular matrix turnover or fibrogenic cell changes. A better understanding of the pathophysiology of liver fibrosis has prompted investigators to use more refined markers to identify different fibrosis stages. Unfortunately, we did not have data on such markers. The Enhanced Liver Fibrosis test is an example of a panel of direct markers, which highlight matrix turnover. The Enhanced Liver Fibrosis panel has been reported to have good diagnostic accuracy to discriminate advanced fibrosis in NAFLD patients. 33 However, its ability to predict future mortality and liver-related complications has not been studied. A combination of indirect and direct markers, such as the LINKI algorithm, 34 may have even better ability to noninvasively distinguish advanced fibrosis and its prognostic ability should also be evaluated in future studies.
Conclusions
In this retrospective cohort study, the NFS and FIB-4 best predicted overall mortality and severe liver disease after a mean follow-up close to 20 years. However, no score had a clinically acceptable predictive capacity, why new scores aimed directly at predicting prognoses in NAFLD are needed.
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